Mosaic ImmunoEngineering (CPMV) Accumulated Expenses (2011 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Accumulated Expenses of $4.4 million for Q1 2026, up 581.06% year-over-year from $641700.0 in Q1 2025, and up 2.73% quarter-over-quarter from $4.3 million in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Accumulated Expenses (2011 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 581.06% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (up 581.06% YoY), while the FY2025 annual figure was $4.3 million, up 557.68% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $4.4 million, up from $4.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $4.4 million in Q1 2026, with the low at $601709.0 in Q1 2023.
- The 5-year median for Accumulated Expenses is $2.8 million (2023), against an average of $2.6 million.
- The sharpest annual moves came in 2025 and 2026: Accumulated Expenses tumbled 80.83% in 2025, then soared 581.06% in 2026.
- Mosaic ImmunoEngineering's Accumulated Expenses stood at $2.4 million in 2022, then surged by 32.75% to $3.2 million in 2023, then sank by 79.69% to $646850.0 in 2024, then jumped by 557.68% to $4.3 million in 2025, then gained by 2.73% to $4.4 million in 2026.
- Business Quant data shows CPMV's Accumulated Expenses at $4.4 million in Q1 2026, $4.3 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.37 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Sep 30, 2025 | 4.14 Mn |
| Jun 30, 2025 | 4.01 Mn |
| Mar 31, 2025 | 641,700.00 |
| Dec 31, 2024 | 646,850.00 |
| Sep 30, 2024 | 3.64 Mn |
| Jun 30, 2024 | 3.51 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 3.18 Mn |
| Sep 30, 2023 | 649,225.00 |
| Jun 30, 2023 | 2.83 Mn |
| Mar 31, 2023 | 601,709.00 |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 2.15 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 1.65 Mn |
| Dec 31, 2021 | 1.39 Mn |
| Sep 30, 2021 | 1.12 Mn |
| Jun 30, 2021 | 1.32 Mn |